Navigation Links
Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
Date:5/8/2008

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release and oral statements made by the Company, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2008 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes
'/>"/>

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
2. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
6. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
7. BD to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
10. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... wealthy as the United States, it may come as a ... to adequate food due to lack of money or other ... at the University of Illinois using data from the National ... who are dealing with hunger are also facing negative health ... Americans over age 60 faced the threat of hungerthat translates ...
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... is the standard measurement for assessing glycemic control over ... are typically measured every few months in a laboratory, ... accurately estimates A1c using self-monitored blood glucose (SMBG) readings, ... ( DTT ), a peer-reviewed journal from Mary Ann ... the DTT website at http://www.liebertpub.com/dtt . ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... "Occlusions in the retinal vein could not only make you loose ... veins is so painful that the eye may have to be ... new instrument that uses a plasma to shoot tiny bullets ... vessels that supply blood to the retina drain into a single ...
... market is currently dominated by the Mumbai based ... company, is planning to enter the anti-AIDS drugs ... and west Asia, S D Kaul, the company ... Aabacavir and Indinavir products in the Indian market ...
... that can have Complication as its other name. Among the ... be the foot ulcer, as damage can be severe enough ... ulcer, a boon in disguise would be a new device ... //Such an electrical stimulation would help in the healing of ...
... procedure widely used on knees can also repair damaged ... best known for repairing knee injuries, but it is ... it is a minimally invasive surgical technique it is ... relieve different ankle problems, including ligament damage, bone chips ...
... basis. One of these latest laser techniques is helpful in ... This degenerative condition cause blood vessels to grow underneath the ... ,Eye specialists have come up with a new therapy ... of damaging the retinal tissue. ,This is a two-step ...
... active ingredient is Acetaminophen is found effective in the ... temperature in people who have had a stroke, according ... ,Rise in the body temperature during the first few ... fever, has been linked to poorer outcomes including an ...
Cached Medicine News:Health News:Blocked viens block eye sight 2Health News:Arthroscopy for Ankles 2
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... April 20 Scientists from the Barbara ... presented data at the American Association for ... represents significant research advancements in the treatment ... breast cancer.(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO )Karmanos researchers discovered ...
... Improves Survival in Animals with Clinical Symptoms of ... 20 Elusys Therapeutics, Inc. (Elusys), ... the treatment of life-threatening infectious diseases, today announced ... safety trial of Anthim(TM), a high-affinity humanized ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference 2Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference 3Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study 2Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study 3
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: